Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Dowell

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 20, 2015
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)Taofeek K Owonikoko, Suzanne E Dahlberg, Saad A Khan, et al.
Investigational New Drugs|April 5, 2020
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancerNobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancerPuneeth Iyengar, Brian D Kavanagh, Zabi Wardak, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2015
Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation TrialKenneth D Westover, Billy W Loo, David E Gerber, et al.
Clinical Lung Cancer|June 22, 2025
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase InhibitorsJ Nicholas Bodor, Jonathan Dowell, Joseph Treat, et al.
JAMA Oncology|August 12, 2021
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical TrialPuneeth Iyengar, Elizabeth Zhang-Velten, Laurence Court, et al.
The Journal of Clinical Investigation|April 4, 2018
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancerKe Gong, Gao Guo, David E Gerber, et al.
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
JTO Clinical and Research Reports|November 14, 2025
Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLCKai-Lin Liu, Alex Watts, Connor B Grady, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 10, 2025
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025Gregory J Riely, Douglas E Wood, Dara L Aisner, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|May 20, 2015
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)Taofeek K Owonikoko, Suzanne E Dahlberg, Saad A Khan, et al.
Investigational New Drugs|April 5, 2020
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancerNobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancerPuneeth Iyengar, Brian D Kavanagh, Zabi Wardak, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2015
Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation TrialKenneth D Westover, Billy W Loo, David E Gerber, et al.
Clinical Lung Cancer|June 22, 2025
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase InhibitorsJ Nicholas Bodor, Jonathan Dowell, Joseph Treat, et al.
JAMA Oncology|August 12, 2021
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical TrialPuneeth Iyengar, Elizabeth Zhang-Velten, Laurence Court, et al.
The Journal of Clinical Investigation|April 4, 2018
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancerKe Gong, Gao Guo, David E Gerber, et al.
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
JTO Clinical and Research Reports|November 14, 2025
Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLCKai-Lin Liu, Alex Watts, Connor B Grady, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 10, 2025
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025Gregory J Riely, Douglas E Wood, Dara L Aisner, et al.
Pageof 4